跳轉至內容
Merck
  • Probe-Dependent Negative Allosteric Modulators of the Long-Chain Free Fatty Acid Receptor FFA4.

Probe-Dependent Negative Allosteric Modulators of the Long-Chain Free Fatty Acid Receptor FFA4.

Molecular pharmacology (2017-04-08)
Kenneth R Watterson, Steffen V F Hansen, Brian D Hudson, Elisa Alvarez-Curto, Sheikh Zahir Raihan, Carlos M G Azevedo, Gabriel Martin, Julia Dunlop, Stephen J Yarwood, Trond Ulven, Graeme Milligan
摘要

High-affinity and selective antagonists that are able to block the actions of both endogenous and synthetic agonists of G protein-coupled receptors are integral to analysis of receptor function and to support suggestions of therapeutic potential. Although there is great interest in the potential of free fatty acid receptor 4 (FFA4) as a novel therapeutic target for the treatment of type II diabetes, the broad distribution pattern of this receptor suggests it may play a range of roles beyond glucose homeostasis in different cells and tissues. To date, a single molecule, 4-methyl-